Tag: in vitro diagnostic in cardiology and neurology market outlook

Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.

In Vitro Diagnostic (IVD) In Cardiology And Neurology Market Value Expansion And Long-Term Growth Outlook

Cardiovascular and neurological in vitro diagnostics (IVD) have experienced robust expansion, projecting a market value increase from $17.22 billion in 2025 to $18.71 billion in 2026, fueled by an 8.7% compound annual growth rate. This upward trajectory in the preceding years owes much to the escalating rates

The in vitro diagnostic market segment dedicated to cardiology and neurology is poised for considerable expansion over the upcoming years, projected to reach a valuation of $25.18 billion by 2030, driven by a compound annual growth rate of 7.7%. This anticipated growth trajectory is underpinned by several key factors, including an aging global populace, escalating demand for tailored diagnostic solutions, the proliferation of point-of-care testing capabilities, increased healthcare spending within developing economies, and a broader embrace of molecular diagnostic methodologies. Furthermore, the coming years are expected to witness significant trends such as a heightened emphasis on early identification of diseases, wider utilization of on-site cardiac and neurological diagnostic tools, advancements in diagnostics based on biomarkers, a greater focus on proactive and predictive healthcare measures, and the incorporation of comprehensive diagnostic suites capable of analyzing multiple parameters.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=15829&type=smp

In Vitro Diagnostic (IVD) In Cardiology And Neurology Market Industry Drivers: What Is Driving Revenue Growth?

The burgeoning field of personalized medicine is poised to significantly propel the expansion of the in vitro diagnostic (IVD) market within the cardiology and neurology sectors. Personalized medicine, which involves customizing healthcare strategies, interventions, and therapeutic regimens based on an individual’s unique characteristics, is experiencing a surge in adoption. This growth is attributable to several key drivers, including progress in genomic technologies, a deeper comprehension of disease pathologies, patient advocacy for bespoke treatments, and supportive regulatory frameworks. IVD tests employed in cardiology and neurology play a pivotal role in enabling this personalized approach by furnishing vital insights into a patient’s genetic predispositions and current health status, thereby informing the development of customized treatment plans aimed at enhancing therapeutic outcomes and mitigating adverse effects. As an illustration, the Personalized Medicine Coalition (PMC), a US-based non-profit research entity, reported that in February 2024, the U.S. Food and Drug Administration granted approval for sixteen novel personalized treatments for individuals with rare diseases in the year 2023, a notable increase from the six approvals seen in 2022; furthermore, these 2023 approvals extended to seven oncological therapies and three treatments designed for a variety of other medical conditions. Consequently, the growing prevalence of personalized medical interventions is a primary impetus behind the expanding in vitro diagnostic (IVD) market in cardiology and neurology.

In Vitro Diagnostic (IVD) In Cardiology And Neurology Market Segment Performance And Strategic Opportunities

The in vitro diagnostic (ivd) in cardiology and neurology market covered in this report is segmented –

1) By Product Type: Instruments, Reagents And Consumables, Software And Services

2) By Technology: Immunoassays, Molecular Diagnostics, Hematology, Other Technologies

3) By End-User: Hospitals, Clinical Laboratories, Other End-Users

Subsegments:

1) By Instruments: Diagnostic Analyzers, Point-Of-Care Devices

2) By Reagents And Consumables: Diagnostic Reagents, Test Kits, Assay Consumables

3) By Software And Services: Diagnostic Software, Data Management Software, IVD Consulting And Support Services

#In Vitro Diagnostic (IVD) In Cardiology And Neurology Market Growth Trends: What Is Influencing The Future Outlook?

The prevalence of AI-powered integrated epigenetic platforms is growing among leading enterprises in the in vitro diagnostic (IVD) sector focused on cardiology and neurology, with these advancements primarily aimed at facilitating early disease identification and risk stratification. These sophisticated AI epigenetic systems incorporate machine-learning algorithms and cutting-edge biomarker assessment methodologies to bolster the precision and reliability in diagnosing and overseeing cardiovascular ailments, thereby tackling significant catalysts for disease advancement. A prime illustration of this trend occurred in February 2023 when Cardio Diagnostics Holdings Inc., a biotechnology firm based in the United States, introduced PrecisionCHD, an AI-driven blood assay engineered for the proactive identification of coronary heart disease (CHD). This innovative test, powered by the company’s proprietary integrated epigenetic-genetic platform, is instrumental in assessing CHD susceptibility and endeavors to both forestall and diagnose the most prevalent manifestation of cardiovascular pathology. By synergizing epigenetic and genetic markers with machine-learning computational models, the PrecisionCHD assay achieves an impressive sensitivity exceeding 75% for both male and female patients. Furthermore, it establishes a correlation between an individual’s biomarker signature and actionable risk factors that significantly contribute to CHD, such as tobacco use, diabetes, elevated blood pressure, and high cholesterol levels. Offering a less invasive approach compared to conventional diagnostic procedures like exercise stress tests or angiograms, PrecisionCHD requires only a simple blood draw, which can be performed conveniently in a clinical setting or even at a patient’s residence.

In Vitro Diagnostic (IVD) In Cardiology And Neurology Market Key Players: Which Companies Shape Industry Competition?

Major companies operating in the in vitro diagnostic (ivd) in cardiology and neurology market are F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Abbott Laboratories, Danaher Corporation, Siemens Healthineers AG, Becton Dickinson And Company, Quest Diagnostics Incorporated, Hologic Inc., Illumina Inc., Beckman Coulter Inc., Quidel Corporation, Sysmex Corporation, Bio-Rad Laboratories Inc., QIAGEN N.V., Instrumentation Laboratory, bioMérieux SA, Natera, Inc., Randox Laboratories Ltd., Fulgent Genetics Inc., DiaSorin S.p.A., Oxford Nanopore Technologies, Fujirebio Diagnostics Inc., Adaptive Biotechnologies, Biocartis Group NV, Agena Bioscience

Access The Complete In Vitro Diagnostic (IVD) In Cardiology And Neurology Market Report:

https://www.thebusinessresearchcompany.com/report/in-vitro-diagnostic-ivd-in-cardiology-and-neurology-global-market-report

In Vitro Diagnostic (IVD) In Cardiology And Neurology Market Largest Region: Which Geography Holds The Highest Market Share?

North Americawas the largest region in the in vitro diagnostic (IVD) in cardiology and neurology market in 2025. Asia-Pacificis expected to be the fastest-growing region in the forecast period. The regions covered in the in vitro diagnostic (ivd) in cardiology and neurology market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Is The Estimated Growth In Market Size Of The In Vitro Diagnostic (IVD) In Cardiology And Neurology Market During 2026–2030?

The market size for in vitro diagnostic (IVD) products in cardiology and neurology has experienced robust growth in recent years. Forecasts indicate an expansion from $17.22 billion in 2025 to $18.71 billion by 2026, achieving a compound annual growth rate (CAGR) of 8.7%. This historical expansion can be linked to several factors, including the increasing prevalence of cardiovascular conditions, a rise in neurological disorder cases, the development of hospital diagnostic facilities, innovations in immunoassay techniques, and heightened clinical understanding of the importance of early diagnosis.

The in vitro diagnostic (ivd) in cardiology and neurology market size is anticipated to experience robust expansion over the next few years. It is projected to reach $25.18 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 7.7%. This expansion during the forecast period is driven by factors such as an aging global demographic, increasing demand for personalized diagnostics, the proliferation of point-of-care testing facilities, rising healthcare expenditure within emerging markets, and the wider adoption of molecular diagnostics. Prominent trends expected in this period include an escalating demand for early disease detection, the growing acceptance of point-of-care cardiac and neuro tests, the broadening of biomarker-based diagnostics, a heightened focus on preventive and predictive testing, and the integration of multi-parameter diagnostic panels.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=15829&type=smp

Which Strategic Drivers Are Supporting The In Vitro Diagnostic (IVD) In Cardiology And Neurology Market Development?

The projected increase in personalized medicine is anticipated to stimulate the expansion of the in vitro diagnostic (IVD) in cardiology and neurology market. Personalized medicine describes a medical strategy where healthcare choices, methods, interventions, and therapies are customized based on each patient’s unique attributes. This approach is gaining traction due to progress in genomics, enhanced comprehension of disease mechanisms, patient desire for customized treatments, and regulatory backing, among other elements. In vitro diagnostic (IVD) tests in cardiology and neurology are instrumental in advancing personalized medicine by offering vital data concerning an individual’s genetic profile and disease state, thereby informing customized treatment strategies for better effectiveness and reduced dangers. For example, in February 2024, the Personalized Medicine Coalition (PMC), a US-based nonprofit research organization, reported that the U.S. Food and Drug Administration sanctioned 16 novel personalized treatments for rare disease patients in 2023, marking an increase from six approvals in 2022, with the 2023 approvals additionally covering seven oncology therapies and three treatments aimed at various other ailments. Consequently, the rising adoption of personalized medicines is propelling the growth of the in vitro diagnostic (IVD) in cardiology and neurology market.

How Is The In Vitro Diagnostic (IVD) In Cardiology And Neurology Market Structured Across Different Market Segments?

The in vitro diagnostic (ivd) in cardiology and neurology market covered in this report is segmented –

1) By Product Type: Instruments, Reagents And Consumables, Software And Services

2) By Technology: Immunoassays, Molecular Diagnostics, Hematology, Other Technologies

3) By End-User: Hospitals, Clinical Laboratories, Other End-Users

Subsegments:

1) By Instruments: Diagnostic Analyzers, Point-Of-Care Devices

2) By Reagents And Consumables: Diagnostic Reagents, Test Kits, Assay Consumables

3) By Software And Services: Diagnostic Software, Data Management Software, IVD Consulting And Support Services

Which Trends Are Expected To Shape The In Vitro Diagnostic (IVD) In Cardiology And Neurology Market?

Leading companies operating within the in vitro diagnostic (IVD) market for cardiology and neurology are actively developing AI-enabled integrated epigenetic engines aimed at early disease detection and risk assessment. These AI-powered integrated epigenetic engines harness machine-learning models and sophisticated biomarker analysis techniques to elevate the sensitivity and accuracy in diagnosing and monitoring cardiovascular diseases, thereby addressing significant factors driving disease progression. For instance, in February 2023, Cardio Diagnostics Holdings Inc., a US-based biotechnology firm, launched PrecisionCHD, an AI-based blood test designed for the early identification of coronary heart disease (CHD). Utilizing the company’s integrated epigenetic-genetic engine, this test assesses CHD risk and seeks to prevent and detect the most prevalent form of cardiovascular disease. The innovative test integrates epigenetic and genetic biomarkers with machine-learning algorithms, providing over 75% sensitivity for both men and women. It connects a patient’s biomarker profile to modifiable risk factors that are major contributors to CHD, such as smoking, diabetes, hypertension, and high cholesterol. PrecisionCHD offers a non-invasive alternative to exercise stress tests or angiograms, with blood samples capable of being drawn in-office or at home.

Which Companies Are Engaged In The In Vitro Diagnostic (IVD) In Cardiology And Neurology Market Environment?

Major companies operating in the in vitro diagnostic (ivd) in cardiology and neurology market are F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Abbott Laboratories, Danaher Corporation, Siemens Healthineers AG, Becton Dickinson And Company, Quest Diagnostics Incorporated, Hologic Inc., Illumina Inc., Beckman Coulter Inc., Quidel Corporation, Sysmex Corporation, Bio-Rad Laboratories Inc., QIAGEN N.V., Instrumentation Laboratory, bioMérieux SA, Natera, Inc., Randox Laboratories Ltd., Fulgent Genetics Inc., DiaSorin S.p.A., Oxford Nanopore Technologies, Fujirebio Diagnostics Inc., Adaptive Biotechnologies, Biocartis Group NV, Agena Bioscience

Access The Complete In Vitro Diagnostic (IVD) In Cardiology And Neurology Market Report:

https://www.thebusinessresearchcompany.com/report/in-vitro-diagnostic-ivd-in-cardiology-and-neurology-global-market-report

What Is The Largest Regional Market In The In Vitro Diagnostic (IVD) In Cardiology And Neurology Market?

North America was the largest region in the in vitro diagnostic (IVD) in cardiology and neurology market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the in vitro diagnostic (ivd) in cardiology and neurology market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access In Vitro Diagnostic (IVD) In Cardiology And Neurology Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/customise?id=15829&type=smp

Browse Through More Reports Similar to the Global In Vitro Diagnostic (IVD) In Cardiology And Neurology Market 2026, By The Business Research Company

In Vitro Diagnostics Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/in-vitro-diagnostics-global-market-report

In Vitro Diagnostics Ivd Quality Control Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/in-vitro-diagnostics-ivd-quality-control-global-market-report

Bioinformatics In In Vitro Diagnostics Ivd Testing Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/bioinformatics-in-in-vitro-diagnostics-ivd-testing-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Is The Anticipated Rise In Market Value Of The In Vitro Diagnostic (IVD) In Cardiology And Neurology Market During The Forecast Period?

The market size for in vitro diagnostic (ivd) in cardiology and neurology has experienced significant growth over recent years. It is anticipated to expand from $17.22 billion in 2025 to $18.71 billion by 2026, exhibiting a compound annual growth rate (CAGR) of 8.7%. This historical growth can be ascribed to factors such as the increasing prevalence of cardiovascular diseases, the rising incidence of neurological disorders, the expansion of hospital diagnostic infrastructure, advancements in immunoassay technologies, and heightened clinical awareness concerning early diagnosis.

The in vitro diagnostic (ivd) in cardiology and neurology market size is projected to experience robust expansion over the coming years. This market is forecast to reach $25.18 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 7.7%. This anticipated growth during the forecast period is primarily driven by factors such as an aging worldwide population, a surging need for personalized diagnostics, the proliferation of point-of-care testing facilities, escalating healthcare spending in developing economies, and the increasing uptake of molecular diagnostics. Key trends anticipated within this period encompass a heightened demand for detecting diseases early, the expanding use of point-of-care cardiac and neuro tests, the broadening scope of biomarker-based diagnostics, an intensified emphasis on preventive and predictive testing, and the incorporation of multi-parameter diagnostic panels.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/report/in-vitro-diagnostic-ivd-in-cardiology-and-neurology-global-market-report

Which Drivers Are Supporting The In Vitro Diagnostic (IVD) In Cardiology And Neurology Market Growth?

The advancement of personalized medicine is anticipated to propel the growth of the in vitro diagnostic (IVD) in cardiology and neurology market moving forward. Personalized medicine describes a medical approach that customizes healthcare decisions, practices, interventions, and treatments to the unique characteristics of each patient. Its expansion is attributed to factors like progress in genomics, enhanced understanding of disease mechanisms, patient demand for tailored treatments, and regulatory support, among others. In vitro diagnostic (IVD) tests in cardiology and neurology contribute to personalized medicine by supplying vital information about an individual’s genetic composition and disease status, thereby guiding customized treatment plans for improved effectiveness and reduced risks. For example, in February 2024, the U.S. Food and Drug Administration approved 16 new personalized treatments for rare disease patients in 2023, according to the Personalized Medicine Coalition (PMC), a US-based nonprofit research organization. This marked an increase from six approvals in 2022, with the 2023 approvals also comprising seven oncology therapies and three treatments targeting various other conditions. Hence, the increasing volume of personalized medicines is a key driver for the expansion of the in vitro diagnostic (IVD) in cardiology and neurology market.

Which Segment Types Are Examined In The In Vitro Diagnostic (IVD) In Cardiology And Neurology Market Segment Study?

The in vitro diagnostic (ivd) in cardiology and neurology market covered in this report is segmented –

1) By Product Type: Instruments, Reagents And Consumables, Software And Services

2) By Technology: Immunoassays, Molecular Diagnostics, Hematology, Other Technologies

3) By End-User: Hospitals, Clinical Laboratories, Other End-Users

Subsegments:

1) By Instruments: Diagnostic Analyzers, Point-Of-Care Devices

2) By Reagents And Consumables: Diagnostic Reagents, Test Kits, Assay Consumables

3) By Software And Services: Diagnostic Software, Data Management Software, IVD Consulting And Support Services

Which Trends Are Expected To Impact The In Vitro Diagnostic (IVD) In Cardiology And Neurology Market?

Leading companies operating within the in vitro diagnostic (IVD) market for cardiology and neurology are concentrating on creating AI-enabled integrated epigenetic engines aimed at early disease detection and risk assessment. These AI-powered integrated epigenetic engines utilize machine-learning models and advanced biomarker analysis techniques to elevate the sensitivity and accuracy in diagnosing and monitoring cardiovascular diseases, thereby tackling critical factors contributing to disease progression. As an example, in February 2023, Cardio Diagnostics Holdings Inc., a US-based biotechnology company, introduced PrecisionCHD, an AI-based blood test specifically engineered for the early identification of coronary heart disease (CHD). Employing the company’s integrated epigenetic-genetic engine, this test assesses CHD risk and endeavors to prevent and detect the most common form of cardiovascular disease. This novel test integrates epigenetic and genetic biomarkers with machine-learning algorithms, achieving over 75% sensitivity for both men and women. It establishes a connection between a patient’s biomarker profile and modifiable risk factors, which are significant contributors to CHD, such as smoking, diabetes, hypertension, and high cholesterol. PrecisionCHD offers a non-invasive substitute for exercise stress tests or angiograms, with blood samples collectable either in a medical office or at home.

Which Players Are Part Of The Competitive Landscape Of The In Vitro Diagnostic (IVD) In Cardiology And Neurology Market?

Major companies operating in the in vitro diagnostic (ivd) in cardiology and neurology market are F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Abbott Laboratories, Danaher Corporation, Siemens Healthineers AG, Becton Dickinson And Company, Quest Diagnostics Incorporated, Hologic Inc., Illumina Inc., Beckman Coulter Inc., Quidel Corporation, Sysmex Corporation, Bio-Rad Laboratories Inc., QIAGEN N.V., Instrumentation Laboratory, bioMérieux SA, Natera, Inc., Randox Laboratories Ltd., Fulgent Genetics Inc., DiaSorin S.p.A., Oxford Nanopore Technologies, Fujirebio Diagnostics Inc., Adaptive Biotechnologies, Biocartis Group NV, Agena Bioscience

Get The Full In Vitro Diagnostic (IVD) In Cardiology And Neurology Market Report:

https://www.thebusinessresearchcompany.com/report/in-vitro-diagnostic-ivd-in-cardiology-and-neurology-global-market-report

Which Region Represents The Largest Share Of The In Vitro Diagnostic (IVD) In Cardiology And Neurology Market?

North America was the largest region in the in vitro diagnostic (IVD) in cardiology and neurology market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the in vitro diagnostic (ivd) in cardiology and neurology market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized In Vitro Diagnostic (IVD) In Cardiology And Neurology Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/in-vitro-diagnostic-ivd-in-cardiology-and-neurology-global-market-report

Browse Through More Reports Similar to the Global In Vitro Diagnostic (IVD) In Cardiology And Neurology Market 2026, By The Business Research Company

Bioinformatics In In Vitro Diagnostics Ivd Testing Market Report 2026

https://www.thebusinessresearchcompany.com/report/bioinformatics-in-in-vitro-diagnostics-ivd-testing-global-market-report

In Vitro Diagnostics Market Report 2026

https://www.thebusinessresearchcompany.com/report/in-vitro-diagnostics-global-market-report

In Vitro Diagnostics Ivd Quality Control Market Report 2026

https://www.thebusinessresearchcompany.com/report/in-vitro-diagnostics-ivd-quality-control-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

How Will The Market Size Of The In Vitro Diagnostic (IVD) In Cardiology And Neurology Market Evolve From 2026 To 2030?

Having shown strong growth in recent years, the in vitro diagnostic (ivd) in cardiology and neurology market size is expected to increase from $17.22 billion in 2025 to $18.71 billion in 2026, with a compound annual growth rate (CAGR) of 8.7%. The historical growth of this market can be ascribed to several factors, including the rising prevalence of cardiovascular diseases, the increasing incidence of neurological disorders, the development of hospital diagnostic infrastructure, advancements in immunoassay technologies, and a greater clinical awareness of early diagnosis.

Significant expansion is anticipated for the in vitro diagnostic (ivd) in cardiology and neurology market size over the coming years. This market is projected to reach $25.18 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 7.7%. Several factors contribute to this growth during the forecast period, including an aging global population, a heightened need for personalized diagnostics, the proliferation of point-of-care testing facilities, increased healthcare spending in developing economies, and the wider embrace of molecular diagnostics. Key trends for the upcoming period encompass a surging demand for the early identification of diseases, a greater uptake of point-of-care cardiac and neuro tests, the broadening of biomarker-based diagnostics, an intensified emphasis on preventive and predictive testing, and the incorporation of multi-parameter diagnostic panels.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=15829&type=smp

Which Growth Drivers Are Contributing To The Progress Of The In Vitro Diagnostic (IVD) In Cardiology And Neurology Market?

The expansion of personalized medicine is anticipated to propel the growth of the in vitro diagnostic (IVD) in cardiology and neurology market. This medical approach customizes healthcare decisions, practices, interventions, and treatments according to the individual characteristics of each patient. Personalized medicine is growing due to advancements in genomics, a better understanding of disease mechanisms, patient demand for tailored treatments, and regulatory support, among other factors. In vitro diagnostic (IVD) tests in cardiology and neurology aid personalized medicine by delivering crucial information regarding an individual’s genetic makeup and disease status, thereby guiding customized treatment plans for enhanced efficacy and reduced risks. For example, in February 2024, as per the Personalized Medicine Coalition (PMC), a US-based nonprofit research organization, the U.S. Food and Drug Administration approved 16 new personalized treatments for rare disease patients in 2023, which was an increase from six approvals in 2022. The 2023 approvals additionally covered seven oncology therapies and three treatments targeting various other conditions. Therefore, the rising number of personalized medicines is significantly contributing to the growth of the in vitro diagnostic (IVD) in cardiology and neurology market.

Which Segment Areas Are Covered In The In Vitro Diagnostic (IVD) In Cardiology And Neurology Market Analysis?

The in vitro diagnostic (ivd) in cardiology and neurology market covered in this report is segmented –

1) By Product Type: Instruments, Reagents And Consumables, Software And Services

2) By Technology: Immunoassays, Molecular Diagnostics, Hematology, Other Technologies

3) By End-User: Hospitals, Clinical Laboratories, Other End-Users

Subsegments:

1) By Instruments: Diagnostic Analyzers, Point-Of-Care Devices

2) By Reagents And Consumables: Diagnostic Reagents, Test Kits, Assay Consumables

3) By Software And Services: Diagnostic Software, Data Management Software, IVD Consulting And Support Services

What Trends Are Affecting The Expansion Of The In Vitro Diagnostic (IVD) In Cardiology And Neurology Market?

Leading companies in the in vitro diagnostic (IVD) in cardiology and neurology market are developing AI-enabled integrated epigenetic engines for early disease detection and risk assessment. These AI-enabled integrated epigenetic engines utilize machine-learning models and advanced biomarker analysis techniques to improve the sensitivity and accuracy in diagnosing and monitoring cardiovascular diseases, thereby addressing critical drivers of disease progression. For example, in February 2023, Cardio Diagnostics Holdings Inc., a US-based biotechnology company, launched PrecisionCHD, an AI-based blood test, specifically designed for the early detection of coronary heart disease (CHD). By leveraging the company’s integrated epigenetic-genetic engine, this test evaluates CHD risk and aims to prevent and detect the most common form of cardiovascular disease. The new test combines epigenetic and genetic biomarkers with machine-learning algorithms, offering over 75% sensitivity for both men and women. It links a patient’s biomarker profile to modifiable risk factors, major contributors to CHD, such as smoking, diabetes, hypertension, and high cholesterol. PrecisionCHD offers a non-invasive alternative to exercise stress tests or angiograms, with blood samples obtainable in-office or at home.

Which Global Companies Are Actively Competing In The In Vitro Diagnostic (IVD) In Cardiology And Neurology Market?

Major companies operating in the in vitro diagnostic (ivd) in cardiology and neurology market are F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Abbott Laboratories, Danaher Corporation, Siemens Healthineers AG, Becton Dickinson And Company, Quest Diagnostics Incorporated, Hologic Inc., Illumina Inc., Beckman Coulter Inc., Quidel Corporation, Sysmex Corporation, Bio-Rad Laboratories Inc., QIAGEN N.V., Instrumentation Laboratory, bioMérieux SA, Natera, Inc., Randox Laboratories Ltd., Fulgent Genetics Inc., DiaSorin S.p.A., Oxford Nanopore Technologies, Fujirebio Diagnostics Inc., Adaptive Biotechnologies, Biocartis Group NV, Agena Bioscience

Read the full in vitro diagnostic (ivd) in cardiology and neurology market report here:

https://www.thebusinessresearchcompany.com/report/in-vitro-diagnostic-ivd-in-cardiology-and-neurology-global-market-report

What Are The Leading Geographic Regions In The In Vitro Diagnostic (IVD) In Cardiology And Neurology Market?

North America was the largest region in the in vitro diagnostic (IVD) in cardiology and neurology market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the in vitro diagnostic (ivd) in cardiology and neurology market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored In Vitro Diagnostic (IVD) In Cardiology And Neurology Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=15829&type=smp

Browse Through More Reports Similar to the Global In Vitro Diagnostic (IVD) In Cardiology And Neurology Market 2026, By The Business Research Company

In Vitro Diagnostics Global Market Report

https://www.thebusinessresearchcompany.com/report/in-vitro-diagnostics-global-market-report

In Vitro Diagnostics Ivd Quality Control Global Market Report

https://www.thebusinessresearchcompany.com/report/in-vitro-diagnostics-ivd-quality-control-global-market-report

Bioinformatics In In Vitro Diagnostics Ivd Testing Global Market Report

https://www.thebusinessresearchcompany.com/report/bioinformatics-in-in-vitro-diagnostics-ivd-testing-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model